Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships

PROTHENA CORP PUBLIC LTD CO

2021-FY EPS reported $1.38 revenue$200,577,000

FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.
Cash and restricted cash $580.4M at Dec 31, 2021, no debt; raised $175M in equity in 2021.
Received $80M BMS option for PRX005, $60M Roche milestone for prasinezumab, $60M upfront from Novo Nordisk for ATTR.
Reached SPA agreement with FDA for confirmatory Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis; Phase 1 of PRX005 initiated.
2022 guidance: net cash used $120-132M; expected net loss $154-170M; ending cash ~$454M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.